KPTI (Karyopharm Therapeutics) 5-Year EBITDA Growth Rate : 19.70% (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Karyopharm Therapeutics 5-Year EBITDA Growth Rate?

Karyopharm Therapeutics's EBITDA per Share for the three months ended in Sep. 2024 was $-0.17.

During the past 3 years, the average EBITDA Per Share Growth Rate was 23.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 19.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Karyopharm Therapeutics was 25.20% per year. The lowest was -32.40% per year. And the median was 4.20% per year.

Competitive Comparison of Karyopharm Therapeutics's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Karyopharm Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karyopharm Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's 5-Year EBITDA Growth Rate falls into.

Karyopharm Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Karyopharm Therapeutics (NAS:KPTI) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Karyopharm Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Karyopharm Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (NAS:KPTI) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

25K:Germany

Address

85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website

https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Executives

Richard A. Paulson	director, officer: President and CEO	85 WELLS AVENUE, NEWTON MA 02459
Michael Mason	officer: EVP, CFO, Treasurer	300 3RD STREET, CAMBRIDGE MA 02142
Michael Mano	officer: SVP, General Counsel&Secretary	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Sohanya Roshan Cheng	officer: SVP Sales & Commercial Ops	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459
Stuart Poulton	officer: EVP, Chief Development Officer	85 WELLS AVENUE, NEWTON MA 02459
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Reshma Rangwala	officer: EVP & Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Garen G Bohlin	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Zhen Su	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Stephen Mitchener	officer: SVP, Chief Business Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Ran Frenkel	officer: EVP, WW Development Operations	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Jatin Shah	officer: EVP, Chief Medical Officer	C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459
Sharon Shacham	officer: C.S.O & Pres. of Res & Develop	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael Kauffman	director, officer: President, C.E.O., C.M.O.	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Peter Honig	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037